spacer
home > ebr > winter 2018 > constant vigilance
PUBLICATIONS
European Biopharmaceutical Review

Constant Vigilance

Wirelessly connected medical devices for monitoring and treating a wide range of illnesses are proliferating. Currently, about 450,000 programmable cardiac pacemakers are implanted in patients, and devices for monitoring and treating conditions including diabetes and sleep apnea are rapidly entering the market (1).

While such network-connected devices have the power to transform patient care by enabling real time monitoring and treatment adjustment, they also present new cybersecurity risks. These range from general malware threats that affect all kinds of computers, routers and smart devices to specifically targeting medical devices to access healthcare computer networks or to hijack the devices themselves.

All of these cybersecurity threats could lead to patient injury or death by disrupting device function, whether intentionally or not. They also may inflict financial damage on product sponsors, prescribing providers and patient users in several ways. To compound the problem, cybersecurity threats constantly change, challenging sponsors and users to keep up with new and ever more sophisticated attacks.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Tony Clarke is Head of Information Security at ICON. Over the last 17 years, he has provided security services to numerous organisations across a number of industries,including life sciences, financial services, utilities, government bodies and EU agencies. Tony holds an MSc in security and forensic computing and numerous cybersecurity certifications. He is currently the open web application security project Dublin Chapter lead. Tony has presented at many security conferences and lectures in ethical hacking on the Dublin Institute of Technology MSc programme.


spacer
Tony Clarke
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI and CSP Technologies, Inc. Announce Strategic Collaboration for Breakthrough Activ-BlisterTM Solutions

Philadelphia, PA & Auburn, AL – September 17, 2018 PCI Pharma Services (PCI), a full-service provider of specialist outsourced drug manufacturing, clinical trial services, and commercial packaging to the global healthcare industry, is pleased to announce its exclusive collaboration agreement with CSP Technologies, Inc. for U.S. clinical trials and stability testing utilizing Activ-BlisterTM packaging solutions, which help protect and promote speed-to-market for pharmaceutical and medical device products with heightened susceptibility to moisture and gases, especially oxygen.
More info >>

White Papers

What is process characterization?

EXPUTEC

Process characterization is an essential step in the commercialization of a new (biological) drug. For drug product commercialization, manufacturers must validate the drug’s manufacturing process. This ensures that the manufacturing process delivers consistently a quality product and that the patient is not at risk.
More info >>

 
Industry Events

SAPHEX 2018

1-2 November 2018, Gallagher Convention Centre, Midrand, South Africa

The SAPHEX exhibition and conference is now established as the “go-to” networking and business event for anyone working in the South African pharmaceutical manufacturing industry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement